US4804540A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for preparing the combination products of triamterene and hydrochlorothiazide
Assignee: GD Searle LLC
•
Filing: 1987-12-16
•
Granted: 1989-02-14
•
Expires: 2007-12-16
Abstract
Abstract A combination pharmaceutical composition is described, together with the process for manufacturing said pharmaceutical composition wherein the active ingredients, namely triamterene and hydrochlorothiazide, are incorporated into a solid dosage form via a single wet granulation process utilizing an acid component. Said process simplifies the formulation and manufacturing, permits greater uniformity, and increases in vitro dissolution.
Inventors
- 👤 Frederic J. Nugent
- 👤 John K. C. Yen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 16:56
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K31/00; A61K31/33; A61K31/395; A61K31/54
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
120 words
A process for producing a pharmaceutically active composition having combined diuretic, antihypokalemic and antihypertensive activity comprising the steps of (a) blending finely divided particles of a triamterene-active pteridine ingredient, a finely-divided hydrochlorothiazide-active benzothiadiazide and pharmaceutically acceptable inert ingredients to form a homogeneous mixture; (b) adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and an acid component in a solvent to form a wet mass; (c) milling of said mass to form granules; and (d) blending the resulting granules with additional pharmaceutically acceptable inert ingredients wherein the weight ratio of said triamterene active ingredient to said hydrochlorothiazide active ingredient in the resulting composition is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 2
Dependent Claim
120 words
A process for producing a pharmaceutically active composition having combined diuretic, antihypokalemic and antihypertensive activity comprising the steps of (a) blending finely divided particles of a triamterene-active pteridine ingredient, a finely-divided hydrochlorothiazide-active benzothiadiazide and pharmaceutically acceptable inert ingredients to form a homogeneous mixture; (b) adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and an acid component in a solvent to form a wet mass; (c) milling of said mass to form granules; and (d) blending the resulting granules with additional pharmaceutically acceptable inert ingredients wherein the weight ratio of said triamterene active ingredient to said hydrochlorothiazide active ingredient in the resulting composition is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 3
Dependent Claim
132 words
A process for producing a phgarmaceutically active composition having combined diuretic, antihypokalemic and antihypertensive activity comprising the steps of (a) blending finely divided particles of triamterene, finely divided particles of hydrochlorothiazide and a wicking, binding, disintegration agent to form a homogeneous mixture; (b) adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and malic acid in the presence of water to form a wet mass; (c) milling of said wet mass to form granules; (d) drying of the wet granules; (e) sizing of the dried granules; and blending of said sized granules with a lubricant agent and a disintegrant agent so that in the resulting composition the weight ratio of said triamterene to said hydrochlorothiazide is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 4
Dependent Claim
132 words
A process for producing a phgarmaceutically active composition having combined diuretic, antihypokalemic and antihypertensive activity comprising the steps of (a) blending finely divided particles of triamterene, finely divided particles of hydrochlorothiazide and a wicking, binding, disintegration agent to form a homogeneous mixture; (b) adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and malic acid in the presence of water to form a wet mass; (c) milling of said wet mass to form granules; (d) drying of the wet granules; (e) sizing of the dried granules; and blending of said sized granules with a lubricant agent and a disintegrant agent so that in the resulting composition the weight ratio of said triamterene to said hydrochlorothiazide is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 5
Dependent Claim
23 words
The process according to claim 2 wherein the amount of malic acid is about 5 to 45 percent on a triamterene weight basis.
Claim 6
Dependent Claim
22 words
The process according to claim 2 wherein the amount of water is about 50 to 650 percent on a triamterene weight basis.
Claim 7
Dependent Claim
16 words
A process according to claim 2 wherein the traimterene:hydrochlorothiazide weight ratio is from 1.25 to 2.00:1.
Claim 8
Dependent Claim
15 words
A process according to claim 5 wherein the traimterene: hydrochlorothiazide weight ratio is about 1.5:1.
Claim 9
Independent Claim
139 words
A method of treating hypertension comprising administering a solid antihypertensive diuretic medication wherein said solid medication is composed essentially of hydrochlorothiazide and triamterene and wherein said solid medication is formed by blending finely divided particles of triamterene, finely divided particles of hydrochlorothiazide and a wicking, binding, disintegration agent to form a homogeneous mixture, adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and malic acid in the presence of water to form a wet mass, milling of said wet mass to form granules, drying of the wet granules, sizing of the dried granules, and blending of said sized granules with a lubricant agent and a disintegrant agent so that in the resulting composition the weight ratio of said triamterene to said hydrochlorothiazide is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 10
Independent Claim
139 words
A method of treating hypertension comprising administering a solid antihypertensive diuretic medication wherein said solid medication is composed essentially of hydrochlorothiazide and triamterene and wherein said solid medication is formed by blending finely divided particles of triamterene, finely divided particles of hydrochlorothiazide and a wicking, binding, disintegration agent to form a homogeneous mixture, adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and malic acid in the presence of water to form a wet mass, milling of said wet mass to form granules, drying of the wet granules, sizing of the dried granules, and blending of said sized granules with a lubricant agent and a disintegrant agent so that in the resulting composition the weight ratio of said triamterene to said hydrochlorothiazide is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 11
Dependent Claim
17 words
A method according to claim 7 wherein said solid medication is formulated as a tablet by compression.
Claim 12
Dependent Claim
15 words
A method according to claim 7 wherein said solid medication is formulated as a capsule.
Claim 13
Dependent Claim
16 words
A method according to claim 7 wherein the triamterene:hydrochlorothiazide weight ratio is from 1.25 to 2.00:1.
Claim 14
Dependent Claim
15 words
A method according to claim 10 wherein the triamterene: hydrochlorothiazide weight ratio is about 1.5:1.
Claim 15
Dependent Claim
125 words
A pharmaceutical combination composition having combined diuretic, antihypokalemic and antihypertensive activity wherein said composition is prepared by blending finely divided particles of triamterene, finely divided particles of hydrochlorothiazide and a wicking, binding, disintegration agent to form a homogeneous mixture, adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and malic acid in the presence of water to form a wet mass, milling of said wet mass to form granules, drying of the wet granules, sizing of the dried granules, and blending of said sized granules with a lubricant agent and a disintegrant agent so that in the resulting composition the weight ratio of said triamterene to said hycrochlorothiazide is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 16
Dependent Claim
125 words
A pharmaceutical combination composition having combined diuretic, antihypokalemic and antihypertensive activity wherein said composition is prepared by blending finely divided particles of triamterene, finely divided particles of hydrochlorothiazide and a wicking, binding, disintegration agent to form a homogeneous mixture, adding to said homogeneous mixture a granulation liquid which is prepared by dispersing/dissolving a suitable binder and malic acid in the presence of water to form a wet mass, milling of said wet mass to form granules, drying of the wet granules, sizing of the dried granules, and blending of said sized granules with a lubricant agent and a disintegrant agent so that in the resulting composition the weight ratio of said triamterene to said hycrochlorothiazide is sufficient to control the hypokalemic effect induced by hydrochlorothiazide.
Claim 17
Dependent Claim
16 words
A composition according to claim 12 wherein the triamterene:hydrochlorothiazide weight ratio is from 1.25 to 2.00:1.
Claim 18
Dependent Claim
14 words
A composition according to claim 13 wherein the triamterene:hydrochlorothiazide weight ratio is about 1.5:1.
References Cited (Backward Citations)
US2853418A
Cited
US3184386A
Cited
US3081230A
Cited
US4139589A
Cited
US4165998A
Cited
US4197289A
Cited
US4168308A
Cited
US4459279A
Cited
US4309406A
Cited
US4248856A
Cited
US4309405A
Cited
US4248857A
Cited
US4255413A
Cited
US4285947A
Cited
US4444769A
Cited
US4526777A
Cited
US4547498A
Cited
US4681765A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-02-14 | 1992-08-15 | 1993-02-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-02-14 | 1996-08-15 | 1997-02-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-02-14 | 2000-08-15 | 2001-02-14 | $7700.00 | Window Closed / Lapsed |